Retatrutide's Phase 3 results are in — and the filing slipped to 2027
By the DoseRoutine Editorial Team · · · How we review content
Eli Lilly reported in July 2026 that retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, met its primary endpoints in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, with weight loss of roughly 20% at 80 weeks on the highest 12 mg dose. Lilly now plans to file for FDA approval in the first quarter of 2027, later than previously guided — so retatrutide remains investigational and is not legally available as an approved medicine anywhere.
- TRIUMPH-2 (obesity or overweight plus type 2 diabetes): up to 20.8% body-weight loss and up to a 1.6-point A1C reduction at 80 weeks on 12 mg.
- Lower doses still worked: roughly 12.7% at 4 mg and 19.1% at 9 mg in TRIUMPH-2.
- TRIUMPH-3 studied severe obesity with established cardiovascular disease — strong weight loss, but the extra cardiovascular benefit over existing drugs is still an open question.
- Regulatory filing moved to Q1 2027, meaning approval realistically lands later in 2027 at the earliest.
- Everything sold as 'retatrutide' today is a research chemical from an unregulated supply chain, not the trial drug.
What retatrutide actually is
Retatrutide is a once-weekly peptide that activates three receptors at once: GLP-1 (appetite and glycemic control), GIP (insulin sensitivity and tolerability) and glucagon (energy expenditure and hepatic fat mobilisation). Semaglutide hits one of those; tirzepatide hits two. The glucagon arm is the differentiator, and it is also why the compound raises heart rate and can nudge liver enzymes and glucose in ways the dual agonists do not.
What the TRIUMPH readouts changed
Before July 2026, the headline retatrutide numbers came from a Phase 2 trial where the top-dose group lost about 24% of body weight at 48 weeks in people without diabetes. Phase 3 in people with type 2 diabetes came in lower — about 20.8% at 80 weeks — which is expected: diabetes consistently blunts weight response across this drug class.
The commercially interesting part is glycemic control. An A1C drop of up to 1.6 points at those weight-loss levels puts retatrutide in the conversation as a diabetes therapy, not only an obesity drug.
What is still unanswered
- Cardiovascular outcomes: weight loss and CV event reduction are not the same endpoint, and the added benefit of the glucagon arm over tirzepatide has not been demonstrated.
- Lean mass: no trial in this program was designed around body composition, so the muscle question stays open (see our post on the myostatin and activin combinations).
- Tolerability at 12 mg over multi-year use, including heart-rate elevation.
- Discontinuation: as with every incretin, weight regain after stopping is the default unless behavior and lean mass are preserved.
What this means if you are tracking a stack
Nothing about the TRIUMPH data makes gray-market retatrutide safer. Trial participants received titrated, sterile, assayed drug with clinician monitoring of A1C, heart rate, liver enzymes and lipids. Vials bought online match none of those conditions, and dose errors in the microgram-to-milligram conversion are the single most common failure we see.
If you are on any incretin, the tracking that matters is boringly practical: dose and date logged, injection sites rotated, weight and waist trended alongside a lean-mass proxy, and a standing note of every interacting medicine (insulin and sulfonylureas above all, because dose reductions are usually needed as weight falls).
This is a summary of published research for general information. Investigational drugs are not available outside clinical trials, and research chemicals sold online are not the same products. Talk to a clinician who knows your history and labs before changing anything you take.
Frequently asked questions
Is retatrutide FDA approved in 2026?
No. As of August 2026 retatrutide is investigational. Lilly announced positive Phase 3 TRIUMPH-2 and TRIUMPH-3 results in July 2026 and plans to submit a regulatory filing in the first quarter of 2027, so an approval decision would come later in 2027 at the earliest.
How much weight did people lose on retatrutide in Phase 3?
In TRIUMPH-2, adults with obesity or overweight plus type 2 diabetes lost up to 20.8% of body weight (about 49.6 lb) at 80 weeks on the 12 mg dose, with 19.1% at 9 mg and 12.7% at 4 mg, alongside A1C reductions of up to 1.6 points.
Is retatrutide better than tirzepatide?
On weight loss the top-line numbers look at least as strong, and the Phase 2 data in people without diabetes were higher. But the trials were not head to head, no cardiovascular outcome advantage has been shown, and tirzepatide is approved while retatrutide is not. 'Better' is not established.
Why did the FDA filing get delayed to 2027?
Lilly moved its expected submission from late 2026 to the first quarter of 2027 as the Phase 3 program reported out. The company framed it as completing the data package rather than a safety problem.
Is research-grade retatrutide the same as the trial drug?
No. Compounds sold as research chemicals are not manufactured, assayed or filled to pharmaceutical standards, and purity, actual peptide content and sterility are unverified. They also carry no titration schedule or medical monitoring, which is where most harm occurs.
Where to track this
- the best GLP-1 tracking apps compared for 2026 — How dose logging, titration history and side-effect notes differ across apps.
- how DoseRoutine handles GLP-1 protocols week to week — Weekly shot reminders, titration steps and missed-dose handling.
- tracking peptides, supplements and hormones in one place — Why a single timeline beats three separate apps when protocols overlap.
Related guides & tools
Matched to the compounds and mechanisms covered in this update.
Related updates
Other posts covering the same compounds, mechanisms and trial phases.
Keep reading
About the author
DoseRoutine Editorial Team — Maintainers of the DoseRoutine compound library and interaction rule set
The DoseRoutine Editorial Team maintains the compound library and the interaction rule set behind DoseRoutine.
We summarize published trials, regulatory documents (FDA, EMA) and company announcements into plain-English updates. Every factual claim on a post is tied to a linked source below.
Posts are written and reviewed by the editorial team, not by a licensed clinician. This is educational reference content — it never recommends an amount for you to take.
Sources & references
4 sources — primary literature, regulatory documents and company announcements, each linked to the original document. Last reviewed . How we select and review sources.
- AnnouncementEli Lilly. Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials. July 23, 2026. View source on prnewswire.com
- ReferenceBioSpace. Lilly preps FDA run for 'triple-G' weight loss drug with Phase 3 data. July 23, 2026. View source on biospace.com
- ReferenceBioPharma Dive. Lilly, with new data, to seek FDA approval of obesity drug retatrutide. July 23, 2026. View source on biopharmadive.com
- Peer-reviewedJastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514–526. View source on pubmed.ncbi.nlm.nih.gov